Kyprolis® (carfilzomib)

Kyprolis®  (pronounced “kye-PRO-lis”) is the second drug to have been developed in a new class of drugs called proteasome inhibitors and approved by the US Food and Drug Administration (FDA). Proteasome inhibitors work by blocking the activity of enzyme complexes called proteasomes. Both normal cells and cancer cells contain proteasomes, which break down damaged and unwanted proteins into smaller components. Proteasomes also carry out the regulated breakdown of undamaged proteins in the cell, a process that is necessary for the control of many critical cellular functions. These smaller components are then used to create new proteins required by the cell. Proteasomes can be thought of as crucial to the cell’s “recycling” of proteins

For more information about Kyprolis, please visit their website

General Information

Kyprolis website

KYPROLIS® (carfilzomib) for Injection is a type of prescription medicine used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma.

Amgen Assist 360

Amgen Assist 360 is a comprehensive patient and caregiver support and services program designed to help patients navigate the treatment journey, including reimbursement and payment support, treatment support and referrals to third-party organizations for day-to-day and emotional support. 

Understanding Kyprolis® (carfilzomib) for injection

This booklet discusses Kyprolis, the results of clinical trials with Kyprolis, how and when it is administered, its possible side effects, and how to manage them. 

Kyprolis® for injection tip card

This handy tip card includes indications, dosage, and potential side effects.

Possible Side Effects


Fatigue is the most common side effect associated with Kyprolis therapy, one that can appear with increasing severity over time. See the IMF publication, Understanding Fatigue, for further information about this topic and about anemia.


Red blood cells contain hemoglobin, a protein that contains iron and transports oxygen from the lungs to the body’s organs and tissues. When a patient has anemia, the result is low levels of oxygen in the body, which may cause shortness of breath and feelings of exhaustion. As with fatigue, anemia is not an immediate effect of Kyprolis, but one that appears with duration of treatment.


Nausea may occur while taking Kyprolis, but it is usually not severe. If vomiting occurs and leads to dehydration, the patient may experience dizziness, light-headedness, or fainting. Medical treatment may be required for dehydration.

Thrombocytopenia (decreased platelet levels)

Patients taking Kyprolis often experience thrombocytopenia – a lowered level of platelets in the blood. Platelets help blood to clot; fewer platelets can lead to bruising, bleeding, and slower healing. The platelet level decreases with treatment but, after the required interval between doses, should return to the baseline level by the beginning of the next cycle.

Dyspnea (shortness of breath)

Shortness of breath can result from many causes, including heart and/or lung problems, anemia, deconditioning (lack of exercise), and obesity. If there is a sudden change in your breathing, it is especially important that you contact your doctor right away. There have been reports of heart and lung disorders in patients receiving Kyprolis, so shortness of breath can be a sign of a serious problem, and should be reported to your healthcare providers promptly.


Diarrhea may occur while taking Kyprolis. Dizziness, lightheadedness, or fainting may occur due to dehydration caused by either excessive or persistent diarrhea.


Fever can signal bacterial or viral infection, an adverse reaction to a drug, or in rare cases, an aggressive myeloma relapse. Since fever could be the sign of a life-threatening condition, you should report this problem immediately. The combination of fever and shortness of breath is of special concern. If this occurs, the patient must have immediate treatment.

Other side effects of Kyprolis

Other side effects can occur with Kyprolis, but they are much less frequent. These de effects include heart problems, tumor lysis syndrome (TLS), lung disorders, and liver problems. You will be monitored carefully during treatment for any signs of these problems. If you have questions or concerns about any of these potential issues, you should discuss them with your treating physician.

Clinical Trials

ARROW clinical trial fact sheet

A Randomized, Open-label, Phase III Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib (Kyprolis®) in Combination with Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing

ENDEAVOR clinical trial fact sheet

Phase III Study with Carfilzomib & Dexamethasone vs Velcade & Dexamethasone for Relapsed MM Patients. Sites actively opening, so call the Hotline for the most up-to-date listings.

Open Kyprolis® (carfilzomib) trials is a registry of federally and privately supported clinical trials conducted in the United States and around the world. gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals.